Acute Treatment of Migraine with Zolmitriptan 5mg Orally Disintegrating Tablet
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Objective: To determine the speed of onset of headache response and duration of response with zolmitriptan 5mg orally disintegrating tablet (ODT) in the acute treatment of migraine.
Background: Rapid pain relief is important for migraine sufferers. The early efficacy (30 minutes) of the 5mg dose of the zolmitriptan ODT formulation was evaluated.
Methods: In this double-blind, parallel-group trial, 670 patients were randomised to receive either zolmitriptan 5mg ODT (n = 329) or matching placebo (n = 341) to treat two migraine headaches of moderate or severe intensity.
Results: Zolmitriptan 5mg ODT was significantly more effective than placebo in achieving a headache response (reduction in migraine headache intensity from moderate or severe to mild or no pain) at 30 minutes (16.5% vs 12.5%; p = 0.048; primary endpoint), 1 hour (p < 0.0001), and 2 hours (p < 0.0001). Significantly more patients achieved a sustained headache response for 24 hours with zolmitriptan 5mg ODT than with placebo (42.5% vs 16.4%; p < 0.0001). Zolmitriptan 5mg ODT also produced a higher pain-free rate than placebo at all timepoints (0.5, 1 and 2 hours post-dose), with the differences becoming significant at 1 hour. Adverse events were reported by 37.7% of the patients treated with zolmitriptan 5mg ODT and 18.1% of the patients treated with placebo. Those that occurred most often for the patients treated with zolmitriptan 5mg ODT were tightness (7.0%), dizziness (6.7%), somnolence (6.7%) and paraesthesias (6.1%).
Conclusions: A significant headache response as early as 30 minutes post-dose and good maintenance of this headache response at 24 hours makes zolmitriptan 5mg ODT an excellent acute treatment for migraine. Together with the relatively low adverse event rate, these data demonstrate that zolmitriptan 5mg ODT is a valuable therapy for migraine sufferers.
- Lipton, RB, Stewart, WF (1997) Prevalence and impact of migraine. Neurol Clin 15: pp. 1-13 CrossRef
- Hu, XH, Markson, LE, Lipton, RB (1999) Burden of migraine in the United States. Arch Intern Med 159: pp. 813-8 CrossRef
- MacGregor, EA, Brandes, J, Eikermann, A (2003) Migraine prevalence and treatment patterns: the global Migraine and Zolmitriptan Evaluation survey. Headache 43: pp. 19-26 CrossRef
- Dowson, AJ, MacGregor, EA, Purdy, RA (2002) Zolmitriptan orally disintegrating tablet is effective in the acute treatment of migraine. Cephalalgia 22: pp. 101-6 CrossRef
- Tfelt-Hansen, P, Block, G, Dahlof, C (2000) Guidelines for controlled trials of drugs in migraine: second edition. Cephalalgia 20: pp. 765-86 CrossRef
- Lipton, RB, Stewart, WF (1999) Acute migraine therapy: do doctors understand what patients with migraine want from therapy?. Headache 39: pp. S20-6 CrossRef
- Marcus, DA (2001) Establishing a standard of speed for assessing the efficacy of the serotonin1B/1D agonists (triptans). Arch Neurol 58: pp. 1056-8 CrossRef
- Rapoport, AM, Ramadan, NM, Adelman, JU (1997) Optimizing the dose of zolmitriptan (Zornig, 311C90) for the acute treatment of migraine: a multicenter, double-blind, placebo-controlled, dose range-finding study. Neurology 49: pp. 1210-8 CrossRef
- Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 8: pp. 1-96
- Acute Treatment of Migraine with Zolmitriptan 5mg Orally Disintegrating Tablet
Volume 18, Issue 15 , pp 1133-1141
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links
- Industry Sectors
- Author Affiliations
- 1. Brigham and Women’s Hospital, Boston, Massachusetts, USA
- 2. Harvard Medical School, Boston, Massachusetts, USA
- 3. New England Center for Headache, Stamford, Connecticut, USA
- 4. Mayo Clinic, Scottsdale, Arizona, USA
- 5. AstraZeneca, Macclesfield, Cheshire, UK